Larry Lo

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 596 citations

Inflammation, Anti-inflammatory, Cardiovascular Disease +10

Raxibacumab for the Treatment of Inhalational Anthrax

Thi-Sau Migone, G. Mani Subramanian, John Zhong et al. · New England Journal of Medicine · 2009 · 286 citations · Full text

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

Sébastien J. Hotte, Hal W. Hirte, Eric X. Chen et al. · Clinical Cancer Research · 2008 · 189 citations

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

F. Anthony Greco, Philip Bonomi, Jeffrey Crawford et al. · Lung Cancer · 2008 · 163 citations

Cancer Immunosurveillance, Medicine, Trail Receptor-1 +7

The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation

Françoise Meylan, Y-J Song, Ivan J. Fuss et al. · Mucosal Immunology · 2010 · 148 citations · Full text

Inflammation, Cytokine, Autoimmune Disease +5